Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 81-90 of 525 results
PAIN Reports, 2020 • July 20, 2020
This pilot study investigated the feasibility and safety of conditioning open-label placebo (COLP) as a pharmacobehavioral intervention to decrease opioid consumption in patients with pain in comprehe...
KEY FINDING: Conditioning open-label placebo significantly reduced total opioid consumption by the end of the intervention period.
Cell Death & Disease, 2020 • July 23, 2020
This article is a correction to a previously published paper in Cell Death & Disease. The original publication had an error where Figure 6 was displayed incorrectly. The correction replaces the incorr...
KEY FINDING: The original article had an error in Figure 6.
Eur J Appl Physiol, 2021 • February 1, 2021
This study investigated the effect of Buspirone, a serotonin agonist, on cardiorespiratory adaptations to FES-exercise training in individuals with acute, high-level SCI. The results suggest that Busp...
KEY FINDING: Patients on Buspirone demonstrated greater increases in peak oxygen consumption compared to the control group (+0.24 ± 0.23 vs. +0.10 ± 0.13 L/min, p=0.08).
Qatar Medical Journal, 2020 • June 11, 2020
This case report describes a 29-year-old male with a spinal cord injury who developed myositis while on gabapentin for neuropathic pain. The patient presented with new-onset generalized muscle pain an...
KEY FINDING: Gabapentin use was associated with the development of myositis in a patient with spinal cord injury, characterized by generalized muscle pain and tenderness.
J Cell Mol Med, 2021 • January 1, 2021
This study investigates the neuroprotective effects of Rehmannioside A (Rea) on spinal cord injury (SCI). The findings demonstrate that Rea inhibits the release of inflammatory factors, promotes M2 mi...
KEY FINDING: Rea treatment inhibited the release of pro-inflammatory mediators from microglial cells in vitro and promoted M2 polarization, protecting co-cultured neurons from apoptosis by suppressing NF-κB and MAPK signaling pathways.
Exp Neurol, 2021 • April 1, 2021
This study investigates the effects of pharmacologically increasing KCC2 activity using CLP257 on spasticity symptoms after chronic SCI in rats. The study also explores how this pharmacological approa...
KEY FINDING: Increasing KCC2 activity with CLP257 improved the rate-dependent depression of the H-reflex in sedentary animals after chronic SCI, indicating improved reflex modulation.
PLoS ONE, 2021 • February 24, 2021
This study demonstrates that SCI accelerates the rate of AD in the aortic arch in a mouse model of AD. Treatment of SCI mice with Salsalate for 4 weeks after injury resulted in a significant decrease ...
KEY FINDING: Spinal cord injury accelerates aortic atherosclerotic disease and associated risk factors in ApoE-/- mice.
Frontiers in Pharmacology, 2021 • February 8, 2021
This study observed that CTP improved functional recovery, reduced the neuronal apoptosis, inhibited inflammation and oxidative stress in SCI mice. miR-142 was up-regulated by CTP, and inhibition of mi...
KEY FINDING: CTP treatment could improve the functional recovery, as well as suppress the apoptosis, alleviate inflammatory and oxidative response in SCI mice.
Scientific Reports, 2021 • April 8, 2021
This study investigated the effect of early escitalopram administration on spasticity after contusive spinal cord injury (SCI) in rats. Escitalopram, a selective serotonin re-uptake inhibitor (SSRI), ...
KEY FINDING: Early escitalopram administration suppressed spastic behaviors during the swimming test in rats with contusive SCI.
J Med Case Reports, 2021 • May 12, 2021
This case report presents a rare instance of a gabapentin-induced coma in a patient with spinal cord injury, successfully reversed by flumazenil. The patient, a 70-year-old man with tetraplegia, exper...
KEY FINDING: A 70-year-old man with tetraplegia developed a coma after gabapentin administration, despite normal renal and liver function.